Keros Therapeutics KROS
NASDAQ KROS
$11.28 -0.07 (-0.62%)
At close: Oct 23, 2026 · 4:00 PM EDT

Keros Therapeutics (KROS) Gains from Sales and Divestitures (2021 - 2025)

Updated

Keros Therapeutics' Gains from Sales and Divestitures came in at -$1,000 for Q4 2025.

Analysis

Keros Therapeutics (KROS) Gains from Sales and Divestitures (2021 - 2025) Analysis & Trends

For FY2025, Keros Therapeutics' Gains from Sales and Divestitures was $13,000.

  • Going back by year, Gains from Sales and Divestitures was -$4,000 in FY2023, -$12,000 in FY2022 and -$46,000 in FY2021.
  • The Q4 2025 figure represents the lowest quarterly Gains from Sales and Divestitures since Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 Keros Therapeutics 223.65 Mn -1.71 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -1,000.00
Mar 31, 2023 -4,000.00
Dec 31, 2022 -1,000.00
Sep 30, 2022 -11,000.00
Dec 31, 2021 -26,000.00
API Access

Keros Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=KROS&period=max&api_key=YOUR_API_KEY